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Methods: A retrospective study was conducted at two medical centers in Taiwan. From May
2002 to August 2010, clinical information and outcome of adults with bacteremic pneumonia
caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae were analyzed. The pri-
mary outcome is the 30-day mortality.
Results: A total of 111 patients with bacteremic pneumonia caused by E. coli (37 patients,
33.3%) and K. pneumoniae (74, 66.7%) were identified. Their mean age was 69.2 years and
51.4% were male patients. Fifty-seven (51.3%) episodes were classified as hospital-acquired in-
fections, 19 (17.1%) as health-care-associated infections, and four (3.6%) as community-f Infectious Diseases, Department of Internal Medicine, National Cheng Kung University Hospital,
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ESBL-producing bacteremic pneumonia 209acquired infections. Fifty-one (45.9%) patients received appropriate empiric antimicrobial
therapy. The 30-day mortality rate was 40.5% (45 patients). In the multivariate analysis,
several independent risk factors, including rapidly fatal underlying disease [odds ratio (OR),
5.75; 95% confidence interval (CI), 1.54e21.48; p Z 0.009], severe sepsis (OR, 4.84; 95% CI,
1.55e15.14; pZ 0.007), critical illness (OR, 4.28; 95% CI, 1.35e13.57; pZ 0.013), and receipt
of appropriate empirical therapy (OR, 0.19; 95% CI, 0.07e0.55; p Z 0.002), were associated
with 30-day mortality. The survival analysis consistently found that individuals with appro-
priate empiric therapy had a higher survival rate (log-rank test, p < 0.001).
Conclusion: ESBL-producing bacteremic pneumonia, especially health-care-associated infec-
tions, often occurred in adults with comorbidities. Appropriate empirical therapy was associ-
ated with a favorable outcome.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Extended-spectrum beta-lactamases (ESBLs) are a het-
erogeneous group of enzymes responsible for the resis-
tance of Gram-negative bacteria to beta-lactam
antibiotics.1 The first ESBL-producing organism was re-
ported in Germany in 1983.2 Pathogens harboring this
characteristic phenotype spread worldwide and had a
serious impact on clinical management of infectious dis-
eases.3 Besides, infections caused by ESBL producers are
associated with a worse outcome than their non-ESBL-
producing counterparts.4
Escherichia coli and Klebsiella pneumoniae are common
ESBL-producing Enterobacteriaceae found worldwide,5 and
cause various infectious diseases in both hospital and
community settings.4,5 According to a previous multicenter
study, E. coli and K. pneumoniae can be the pathogens of
bacteremic nosocomial pneumonia (E. coli, 8.3% and K.
pneumoniae, 13.1%).6 In Taiwan, the annual prevalence
rate of ESBL-producing phenotype among clinical E. coli
and K. pneumoniae isolates was 11.5% and 12.1%, respec-
tively, from 2002 to 2010.7
Because positive blood cultures are uncommon in pa-
tients with pneumonia, the pathogens responsible are
usually isolated from respiratory samples.8,9 Many studies
tried to investigate the potential impact of bacteremic
pneumonia due to a worse outcome.6,10e12 However, clin-
ical studies of bacteremic pneumonia caused by ESBL pro-
ducers are limited. This study is intended to identify
clinical features and risk factors for mortality in patients
with bacteremic pneumonia caused by ESBL-producing E.
coli and K. pneumoniae.
Materials and methods
Patients
A retrospective study among adults (age  18 years) was
conducted in two medical centers in Taiwan, namely, the
National Taiwan University Hospital in Northern Taiwan and
the National Cheng Kung University Hospital in Southern
Taiwan. The list of patients with E. coli and K. pneumoniaebacteremia between May 2002 and August 2010 was
retrieved from the database of clinical microbiology labo-
ratories in the two study hospitals. Information on in-
dividuals with ESBL-producing E. coli and K. pneumoniae
bacteremic pneumonia between May 2002 and August 2007
was included in a previous study.13 A diagnosis of pneu-
monia was made when there were symptoms of lower res-
piratory tract infections (e.g., cough, purulent
expectoration, chest pain) and pulmonary infiltrates on the
chest radiograph not attributable to other causes, coin-
ciding with the isolation of the same isolate in sputum,
bronchoalveolar lavage fluid, or appropriate respiratory
specimens14,15 as the ESBL producer isolated from blood
samples. For those with more than one episode of bacter-
emia caused by the same isolate, only the first episode was
included for analysis.
Antimicrobial susceptibility and ESBL phenotype
detection
Blood samples collected in the blood culture bottles were
incubated in the blood culture system of BACTEC 9240
(Beck Dickinson, Franklin Lakes, NJ, USA). Sputum samples
were plated onto the blood agar. E. coli and K. pneumoniae
were identified by the colony morphology and biochemical
characteristics and confirmed by the VITEK identification
system (bioMe´rieux Inc., Durham, NC, USA).
Antimicrobial susceptibility was determined by the disk
diffusion method, using the method and interpretative
criteria recommended by the Clinical and Laboratory
Standards Institute (CLSI).16 The production of ESBL was
screened and confirmed in accordance with the standards
of CLSI.16
Collection of clinical information
Medical records of eligible cases were reviewed. Clinical
information, including demographic data, comorbidities,
disease severity, complication of bacteremia, laboratory
and microbiology data, antimicrobial treatment, and clin-
ical outcome, was collected using a standardized case
form.
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All study patients with pneumonia were classified into four
groups, namely, community-acquired, health-care-associ-
ated, hospital-acquired, and ventilator-associated pneu-
monia, as defined by the Infectious Diseases Society of
America and the American Thoracic Society.15,17 In brief,
hospital-acquired pneumonia comprises adults with pneu-
monia that were clinically evident after more than 48 hours
of hospitalization. Ventilator-associated pneumonia is
defined as pneumonia occurring more than 48 hours after
the initiation of endotracheal intubation and mechanical
ventilation. Health-care-associated pneumonia includes
any patient who has been hospitalized in an acute care
hospital for 2 or more days within the preceding 90 days,
resided in a nursing home or long-term care facility,
received recent intravenous antibiotic therapy, chemo-
therapy, or wound care within the preceding 30 days, or
attended a hospital or hemodialysis clinic. Community-
acquired pneumonia comprised those unable to fulfill the
definitions of health-care-associated or hospital-acquired
pneumonia. ESBL-producing isolates resistant to both fluo-
roquinolones (ciprofloxacin, levofloxacin, or both) and
aminoglycosides (amikacin or gentamicin, or both) were
defined as being multidrug resistant (MDR). According to
the McCabe score, the severity of underlying medical illness
was stratified as being fatal, ultimately fatal, or nonfatal.18
The severity of bacteremia was evaluated by the Pittsburgh
bacteremia score, and patients with four points or more
were regarded as having a critical illness.19 Patients with
dysfunction of two or more organs were categorized as
having severe sepsis.20
Antimicrobial therapy administered within 5 days after
bacteremia onset was regarded as empirical therapy, and
that administered afterward as definitive therapy. Antimi-
crobial agents were considered to be appropriate if the
causative pathogen was in vitro susceptible to the antimi-
crobial agents. The primary outcome in the study was 30-
day mortality.
Statistical analysis
The results were analyzed by the SPSS software (IBM Corp.,
Armonk, NY, USA) for MAC, version 21.0. Continuous vari-
ables were expressed as mean values  standard de-
viations, and compared by the ManneWhitney U test or
Student t test. Categorical variables were expressed as
percentages of the total number of patients analyzed, and
compared by the Fisher exact test or c2 test, as appro-
priate. Variables with p  0.05 by the univariate analysis
were included in the multiple conditional logistic regression
analysis. A p value < 0.05 was considered statistically sig-
nificant and all tests were two tailed. Survival curves were
prepared by the KaplaneMeier method and analyzed by the
log-rank test.
Results
During the study period, a total of 473 patients with
bacteremia caused by ESBL-producing E. coli (nZ 228) and
K. pneumoniae (n Z 245) were identified. Bacteremicpneumonia was noted in 30.2% (74/245) of K. pneumoniae
bacteremia and in 16.2% (37/228) of E. coli bacteremia
(p < 0.001). Overall, 111 (23.5%) patients fulfilling the
eligible criteria were analyzed. The clinical characteristics
of these patients are presented in Table 1. The mean age of
the patients was 69.2 years and 48.4% were male patients.
Chronic kidney disease (50, 45%) was the most common
underlying disease, followed by diabetes mellitus (43,
38.7%) and malignancy (37, 33.3%). With respect to clinical
settings in which pneumonia developed, four (3.6%) pa-
tients had community-acquired, 19 (17.1%) health-care-
associated, 57 (51.3%) hospital-acquired, and 31 (27.9%)
ventilator-associated pneumonia. E. coli more often caused
community-acquired (10.8% vs. 0%, p Z 0.01) or health-
care-associated (27.0% vs. 12.2%, p Z 0.06) bacteremic
pneumonia than K. pneumoniae. Most ESBL-producing E.
coli or K. pneumoniae isolates (88, 79.3%) were resistant to
at least a fluoroquinolone, and nearly a half of the isolates
(58, 53.3%) were MDR. However, the clinical characteristics
of patients with bacteremic pneumonia caused by K.
pneumoniae or E. coli were similar in terms of age, gender,
underlying diseases, and severity of disease when bacter-
emia developed (Table 1). Of note, there were no signifi-
cant differences in the mortality rate of patients with
bacteremic pneumonia caused by ESBL-producing K. pneu-
moniae or E. coli (Table 1). Therefore, the patients with E.
coli and K. pneumoniae bacteremia were grouped together
for further analysis.
In the univariate analysis, the presence of rapidly fatal
underlying disease (p < 0.001), severe sepsis (p < 0.001),
receipt of inappropriate empirical therapy (p < 0.001),
inappropriate definitive therapy (p < 0.001), and solid
tumor (p Z 0.016) were associated with the 30-day mor-
tality (Table 2). MDR was not significantly related to the
mortality (46.7% vs. 53.3 %, p Z 0.34). By the multivariate
logistic regression analysis, the presence of rapidly fatal
underlying disease [odds ratio (OR), 5.75; 95% confidence
interval (CI), 1.54e21.48; p Z 0.009], severe sepsis (OR,
4.84; 95% CI, 1.55e15.14; p Z 0.007), and critical illness
(OR, 4.28; 95% CI, 1.35e13.57; p Z 0.013), were indepen-
dently associated with the 30-day mortality (Table 2). By
contrast, the receipt of appropriate empirical therapy (OR,
0.19; 95% CI, 0.07e0.55; p Z 0.002) was independently
associated with a better outcome.
To clarify the impact of empirical therapy, survival
analysis was performed, which revealed that the 30-day
mortality rate was lower in patients receiving appropriate
empirical therapy (Fig. 1A) and in those with severe sepsis
(Fig. 1B). Fifty-one (45.9%) patients had received appro-
priate empirical antimicrobial therapy. Of these patients,
49 (96.1%) received monotherapy, including a carbapenem
(nZ 39 patients; ertapenem, imipenem, or meropenem), a
fluoroquinolone (n Z 4; ciprofloxacin or levofloxacin), a b-
lactam/b-lactamase inhibitor (n Z 4), and cephamycin
(n Z 2). The 30-day mortality rate of empirical carbape-
nem monotherapy was 25.6% (10/39) and that of fluo-
roquinolone monotherapy was 25% (1/4). Even if empirical
therapy is defined as the agents used within 3 days of
bacteremia onset, the 30-day mortality rate of those
receiving appropriate empirical therapy was significantly
lower than that of those receiving inappropriate empirical
therapy (23.9%, 11/46 vs. 52.3%, 34/65; p Z 0.003). As for
Table 1 Clinical characteristics of 111 patients with bacteremic pneumonia caused by extended-spectrum beta-lactamase-
producing Escherichia coli or Klebsiella pneumoniae
Characteristics All (n Z 111) E. coli (n Z 37) K. pneumoniae (n Z 74) p
Age (mean  standard deviation), y 69.2  15.0 67.8  16.2 69.9  14.4 0.49
Sex, male 57 (51.4) 21 (56.8) 36 (48.6) 0.55
Underlying disease
Chronic kidney disease 50 (45.0) 12 (32.4) 38 (51.4) 0.07
End-stage renal disease with hemodialysis 33 (29.7) 9 (24.3) 24 (32.4) 0.51
Diabetes mellitus 43 (38.7) 14 (37.8) 29 (39.2) 1.00
Malignancy 37 (33.3) 16 (43.2) 21 (28.4) 0.14
Immunosuppressant therapy 29 (26.1) 14 (27.5) 15 (25.0) 0.83
Liver cirrhosis 12 (10.8) 6 (16.2) 6 (8.1) 0.21
None 16 (19.4) 7 (13.7) 9 (15.0) 1.00
Type of pneumonia
Community-acquired 4 (3.6) 4 (10.8) 0 (0.0) 0.011
Health-care-associated 19 (17.1) 10 (27.0) 9 (12.2) 0.06
Hospital-acquired 57 (51.3) 14 (37.8) 43 (58.1) 0.07
Ventilator-associated 31 (27.9) 9 (24.3) 22 (29.7) 0.66
Critical illness (Pittsburgh bacteremia score  4) 47 (42.3) 17 (45.9) 30 (40.5) 0.68
Severe sepsis 58 (52.3) 23 (62.2) 35 (47.3) 0.16
Appropriate empirical antimicrobial therapy 51 (45.9) 12 (32.4) 39 (52.7) 0.047
Appropriate definitive antimicrobial therapy 90 (81.1) 29 (78.4) 61 (82.4) 0.62
Sepsis-related mortality 41 (36.9) 15 (40.5) 26 (35.1) 0.68
30-d mortality 15 (40.5) 16 (43.2) 29 (39.2) 0.69
Crude mortality 62 (55.9) 21 (56.8) 41 (55.4) 1.00
Data are presented as n (%), unless otherwise specified.
Table 2 Logistic regression analysis for risk factors of 30-d mortality among patients with bacteremic pneumonia caused by
extended-spectrum beta-lactamase producing Escherichia coli or Klebsiella pneumoniae
Variables Number of cases (%) Univariate analysis Multivariate analysis
Fatal
(n Z 45)
Surviving
(n Z 66)
Odds
ratio
95% confidence
interval
p Odds
ratio
95% confidence
interval
p
Age (mean  standard deviation), y 71.4  13.1 67.1  16.1 0.21 0.15
Sex, male 21 (46.7) 36 (54.5) 0.73 0.34e1.56 0.45
Comorbidities
Chronic kidney disease 20 (44.4) 30 (45.5) 0.96 0.45e2.06 1.00
Diabetes mellitus 20 (44.4) 23 (36.7) 1.50 0.69e3.25 0.33
Solid tumor 18 (40.0) 12 (18.2) 3.00 1.26e7.12 0.016 2.09 0.53e8.29 0.30
Immunosuppressant therapy 11 (24.4) 18 (27.3) 0.86 0.37e2.06 0.83
Liver cirrhosis 8 (17.8) 4 (6.1) 3.35 0.94e11.90 0.07
Chronic lung disease 1 (2.2) 4 (4.1) 0.35 0.04e3.26 0.65
None 4 (8.9) 12 (18.2) 0.44 0.13e1.46 0.27
Rapidly fatal underlying disease 18 (40.0) 6 (9.1) 6.67 2.38e18.67 <0.001 5.75 1.54e21.48 0.009
Type of pneumonia
Community-acquired 1 (2.2) 3 (4.5) 0.48 0.05e4.74 0.65
Health-care-associated 9 (20.0) 12 (18.2) 1.13 0.43e2.94 0.81
Hospital-acquired 20 (44.4) 37 (56.1) 0.63 0.29e1.35 0.25
Ventilator-associated 16 (35.6) 15 (22.7) 1.88 0.81e4.34 0.20
Critical illness (Pittsburgh
bacteremia score  4)
30 (66.7) 17 (25.8) 5.76 2.51e13.22 <0.001 4.28 1.35e13.57 0.013
Severe sepsis 37 (82.2) 21 (31.8) 9.91 3.94e24.95 <0.001 4.84 1.55e15.14 0.007
Appropriate empirical antimicrobial
therapy
11 (24.4) 40 (60.6) 0.21 0.09e0.49 <0.001 0.19 0.07e0.55 0.002
Time to appropriate therapy
(mean  standard deviation), d
6.9  6.0 2.8  2.4 <0.001
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Figure 1. Survival curves of patients with ESBL-producing
bacteremic pneumonia with and without appropriate empir-
ical therapy (A), and of severe sepsis patients with and without
appropriate empirical therapy (B). The unbroken line repre-
sents appropriate empirical therapy, and the broken line rep-
resents inappropriate empirical therapy.
212 W.-L. Cheng et al.definitive therapy, appropriate therapy has a survival
beneficial effect at 30 days, when compared with inap-
propriate definitive therapy (28.9%, 26/90 vs. 90.5%, 19/21;
p < 0.001). None of those receiving empirical b-lactam/b-
lactamase inhibitor or cephamycin therapy died. In a sub-
group analysis, the patients with rapidly fatal underlying
disease (11.8% vs. 30%, p Z 0.022), solid tumor (17.6% vs.
35.0%, pZ 0.054), and E. coli infections (67.6 % vs. 47.3 %,
p Z 0.047) were more likely to receive empirical inappro-
priate therapy (Table 3).Discussion
This study demonstrated that 96.4% of ESBL-producing
bacteremic pneumonia was regarded as hospital- or
health-care-associated infections, and approximately one
half of the study population received an inappropriate
empirical antimicrobial therapy, which is associated with ahigher 30-day mortality rate (40.5%). The clinical charac-
teristics of ESBL-producing E. coli and K. pneumoniae
bacteremic pneumonia were described to emphasize the
importance of appropriateness of empirical antibiotics.
Many studies have described the worldwide increase in
ESBL-producing E. coli and K. pneumoniae isolates during
the past decade.7,21,22 In addition, a previous study also
reported that bacteremia caused by ESBL producer was
associated with a longer hospital stay and delayed treat-
ment.23 Diversity of clinical diseases caused by ESBL pro-
ducers, such as bacteremia, urinary tract infection, and
intra-abdominal infection, had been reported and
analyzed.4,24,25 Studies suggest that bacteremia associated
with hospital-acquired pneumonia may lead to a fatality
rate up to 50%,6,10,26 and is independently associated with
higher mortality, which was possibly related to the high
level of antibiotic resistance.6 Pseudomonas aeruginosa is
the leading pathogen of hospital-acquired pneumonia, and
the 30-day mortality rate of P. aeruginosa bacteremic
pneumonia may be up to 51%.27 However, adequate
empirical therapy can decrease mortality in these pa-
tients.27 In our study, the mortality rate of bacteremic
pneumonia due to ESBL-producing Enterobacteriaceae was
40%, and 50% of the patients received inappropriate anti-
biotic therapy initially.
Previous studies of bloodstream infections caused by
ESBL-producing Enterobacteriaceae have reported con-
flicting results regarding the impact of the appropriateness
of empirical therapy on mortality.28e30 Diverse study de-
signs, categorizations of clinical settings, and origins of
bacteremia made the data incomparable between these
studies. Primary bacteremia and respiratory infections-
related bacteremia had the highest mortality, whereas
bacteremia that originated from a urinary tract infection
had the lowest mortality.31 In the aforementioned studies,
inappropriate empirical antibiotic therapy was an inde-
pendent risk factor for mortality in nonurinary tract in-
fections. Accordingly, our study found that inappropriate
empirical or definitive therapy was significantly related to
the 30-day mortality (by the KaplaneMeier analysis,
p < 0.001). Twenty-five (22.5%) patients died within 5 days
after bacteremia onset, and 80% of them received inap-
propriate empirical therapy. This highlights the importance
of initiating early appropriate therapy.
Furthermore, we analyzed the role of fluoroquinolones
in treating pneumonia caused by ESBL producers. Empirical
fluoroquinolone monotherapy is not inferior to carbapenem
in terms of the crude 30-day mortality rate. However, high
resistance to fluoroquinolones (79.3%) was found in our
cohort, and therefore, choosing it as empirical therapy for
covering possible ESBL-producer pneumonia may not be
suitable. However, in areas with low resistance to fluo-
roquinolones, it can be a suitable choice for empirical
therapy to treat bacteremic pneumonia caused by ESBL
producers.
When we compared the patients who received appro-
priate therapy with that of those who received inappro-
priate therapy, it was found that patients with underlying
solid tumor more often received inappropriate empirical
therapy. In our earlier analysis, empirical carbapenem
therapy was prescribed more often to patients with he-
matological malignancy (53.8% vs. 32.2%).24 Because
Table 3 Characteristics of patients receiving appropriate and inappropriate empirical antibiotic therapy
Variables Empirical therapy p
Appropriate (n Z 51) Inappropriate (n Z 60)
Age (mean  standard deviation), y 66.9  15.2 71.1  14.6 0.15
Sex, male 29 (56.9) 28 (46.7) 0.34
Comorbidities
Chronic kidney disease 27 (52.9) 23 (38.3) 0.13
Diabetes mellitus 18 (35.3) 25 (41.7) 0.56
Immunosuppressant therapy 14 (27.5) 15 (25.0) 0.83
Solid tumor 9 (17.6) 21 (35.0) 0.054
Liver cirrhosis 5 (9.8) 7 (11.7) 1.00
Rapidly fatal underlying disease 6 (11.8) 18 (60.0) 0.022
Causative pathogen
Escherichia coli 12 (23.5) 25 (41.7) 0.047
Klebsiella pneumoniae 39 (76.5) 35 (58.3)
Severity of disease
Severe sepsis 23 (45.1) 35 (58.3) 0.19
Organ dysfunction at onset of bacteremia
Respiratory dysfunction 31 (60.8) 28 (46.7) 0.18
Shock 23 (45.1) 38 (63.3) 0.059
Hepatic dysfunction 12 (23.5) 19 (31.7) 0.40
Renal dysfunction 8 (15.7) 11 (18.3) 0.80
Neurological dysfunction 8 (15.7) 18 (30.0) 0.12
Hematological dysfunction 7 (13.7) 16 (26.7) 0.11
Mortality rate
Sepsis-related 9 (17.6) 32 (53.3) <0.001
30-d 11 (21.6) 34 (56.7) <0.001
Crude 24 (47.1) 38 (63.3) 0.13
Data are presented as n (%) unless otherwise specified.
ESBL-producing bacteremic pneumonia 213neutropenia is frequently encountered in patients with a
solid tumor, physicians tended to administer broad-
spectrum antibiotics early during the treatment period in
this group of patients, whereas they administer more
appropriate empirical therapy in patients with hematolog-
ical malignancy (57% vs. 30%). Another possibility is that
those with a solid tumor were older and more likely to have
advanced tumors, and thus empirical antimicrobial therapy
would be conservative. Likewise, the underlying rapidly
fatal diseases were mainly referred to malignancy and led
to a similar scenario as in the aforementioned clinical
setting. With regard to the causative pathogens, those with
E. coli bacteremia more often received inappropriate
empirical therapy. It is likely that E. coli was dominant in
community-acquired and health-care-associated pneu-
monia, for which physicians rarely considered ESBL pro-
ducers as causative pathogens and less likely prescribed
carbapenem therapy as empirical therapy.
In ESBL-producer infections, carbapenems have been
widely considered as the drugs of choice. With these
aforementioned findings and the increasing prevalence of
ESBL-producer infections, carbapenem therapy should be
considered for critically ill patients with multiple risk fac-
tors for the treatment of infections caused by MDR organ-
isms. However, such an escalation strategy may be
detrimental to the antimicrobial resistance crisis and cause
a greater extent of carbapenem resistance in Gram-
negative bacteria.32,33 Thus, it is important to find clinical
clues for early identification of infectious diseases causedby ESBL-producing Enterobacteriaceae. Susceptible popu-
lation included those with previous colonization or in-
fections due to ESBL producers, serious illness with
prolonged hospital stay or invasive medical device, prior
therapy with fluoroquinolones or oxyimino-b-lactam agents
(such as cefuroxime, cefotaxime, ceftriaxone, ceftazidime,
or aztreonam).3,34 When confronting these patients with
pneumonia, clinicians should consider ESBL producers as
one of the potential pathogens.
Recent studies focused on increasing ESBL-producer in-
fections, especially urinary tract infections, in the com-
munity setting.4,25,35,36 Only four patients in our cohort
acquired infections in the community, and three survived
for 30 days after bacteremia onset even under inappro-
priate empirical therapy. Peralta et al28 reported that
nosocomial ESBL-producer infections had a worse outcome.
However, our case number of community-acquired pneu-
monia is limited and more clinical studies are warranted to
define the prognostic implication of community-acquired
pneumonia due to ESBL producers. In Taiwan, K. pneumo-
niae is a common pathogen of pneumonia and causes a high
mortality rate, up to 55%, even in the cases of community-
acquired pneumonia.37 Moreover in our study, like K.
pneumoniae, E. coli also caused severe and fatal
pneumonia.
Our study had some limitations. First, it was a retro-
spective study and conducted at two medical centers, and
therefore, there may be selection bias, which limits the
general application of the study results to other areas.
214 W.-L. Cheng et al.Second, our study included only patients with bacteremia,
and thus, our findings may not be applicable to the cases of
ESBL-producer pneumonia without bacteremia.
In conclusion, our study highlights the poor prognosis of
bacteremic pneumonia caused by ESBL-producing E. coli
and K. pneumoniae. Early identification and initiation of
appropriate antimicrobial therapy will improve the clinical
outcome of these patients.
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